Influenza A Virus, H3N2 Subtype Infections – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Influenza A Virus, H3N2 Subtype Infections – Pipeline Review, H1 2017’, provides an overview of the Influenza A Virus, H3N2 Subtype Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Influenza A Virus, H3N2 Subtype Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Influenza A Virus, H3N2 Subtype Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Influenza A Virus, H3N2 Subtype Infections

– The report reviews pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Influenza A Virus, H3N2 Subtype Infections therapeutics and enlists all their major and minor projects

– The report assesses Influenza A Virus, H3N2 Subtype Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Influenza A Virus, H3N2 Subtype Infections

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Influenza A Virus, H3N2 Subtype Infections pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

AIMM Therapeutics BV

Aphios Corp

BiondVax Pharmaceuticals Ltd

Celltrion Inc

FluGen Inc

Glide Pharmaceutical Technologies Ltd

ILiAD Biotechnologies LLC

Inovio Pharmaceuticals Inc

Johnson & Johnson

Medicago Inc

MedImmune LLC

Mucosis BV

NanoViricides Inc

Novavax Inc

OPKO Health Inc

Protein Sciences Corp

Sanofi Pasteur SA

Sarepta Therapeutics Inc

SK Chemicals Co Ltd

Takeda Pharmaceutical Company Ltd

VBI Vaccines Inc

Visterra Inc

Zydus Cadila Healthcare Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Influenza A Virus, H3N2 Subtype Infections - Overview

Influenza A Virus, H3N2 Subtype Infections - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Influenza A Virus, H3N2 Subtype Infections - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Influenza A Virus, H3N2 Subtype Infections - Companies Involved in Therapeutics Development

AbbVie Inc

AIMM Therapeutics BV

Aphios Corp

BiondVax Pharmaceuticals Ltd

Celltrion Inc

FluGen Inc

Glide Pharmaceutical Technologies Ltd

ILiAD Biotechnologies LLC

Inovio Pharmaceuticals Inc

Johnson & Johnson

Medicago Inc

MedImmune LLC

Mucosis BV

NanoViricides Inc

Novavax Inc

OPKO Health Inc

Protein Sciences Corp

Sanofi Pasteur SA

Sarepta Therapeutics Inc

SK Chemicals Co Ltd

Takeda Pharmaceutical Company Ltd

VBI Vaccines Inc

Visterra Inc

Zydus Cadila Healthcare Ltd

Influenza A Virus, H3N2 Subtype Infections - Drug Profiles

APP-0205 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APP-309 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Aspidasept - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AV-5075S - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AV-5080 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cetylpyridinium chloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CR-8020 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CR-8043 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CTP-27 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fluad (quadrivalent) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FluGEM - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gamma-Flu - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H3N2] (monovalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H3N2] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H3N2] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H3N2] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H3N2v] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H3N2v] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + A/H5N1] (virus like particle) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent, virus like particle) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B] (trivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-3872 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NBP-607 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NEO-8877 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NVINF-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NVINF-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides for Influenza Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pertussis [strain BPZE1] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PNSIA-28 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

radavirsen - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REDEE FLU - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for RSV and Influenza A Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VIS-410 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Influenza A Virus, H3N2 Subtype Infections - Dormant Projects

Influenza A Virus, H3N2 Subtype Infections - Discontinued Products

Influenza A Virus, H3N2 Subtype Infections - Product Development Milestones

Featured News & Press Releases

Jan 12, 2017: Study Published in Vaccine Journal Indicates BiondVax’s Universal Flu Vaccine Candidate May Cover Strains Which Don’t Yet Exist

Jun 23, 2016: AstraZeneca provides update on Flumist Quadrivalent Vaccine in the US for the 2016-17 influenza season

Dec 21, 2012: Sarepta Therapeutics Enters Into Clinical Trial Agreement With NIH For Further Development Of Influenza Drug AVI-7100

Oct 09, 2012: NanoViricides's Oral FluCide Drug Candidate Found To Be Superior To Oseltamivir In Reduction Of Virus Load And Lung Damage Pathology In Animal Models With H3N2 Influenza

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Influenza A Virus, H3N2 Subtype Infections – Pipeline by AbbVie Inc, H1 2017

Influenza A Virus, H3N2 Subtype Infections – Pipeline by AIMM Therapeutics BV, H1 2017

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Aphios Corp, H1 2017

Influenza A Virus, H3N2 Subtype Infections – Pipeline by BiondVax Pharmaceuticals Ltd, H1 2017

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Celltrion Inc, H1 2017

Influenza A Virus, H3N2 Subtype Infections – Pipeline by FluGen Inc, H1 2017

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Glide Pharmaceutical Technologies Ltd, H1 2017

Influenza A Virus, H3N2 Subtype Infections – Pipeline by ILiAD Biotechnologies LLC, H1 2017

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Inovio Pharmaceuticals Inc, H1 2017

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Johnson & Johnson, H1 2017

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Medicago Inc, H1 2017

Influenza A Virus, H3N2 Subtype Infections – Pipeline by MedImmune LLC, H1 2017

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Mucosis BV, H1 2017

Influenza A Virus, H3N2 Subtype Infections – Pipeline by NanoViricides Inc, H1 2017

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Novavax Inc, H1 2017

Influenza A Virus, H3N2 Subtype Infections – Pipeline by OPKO Health Inc, H1 2017

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Protein Sciences Corp, H1 2017

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Sanofi Pasteur SA, H1 2017

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Sarepta Therapeutics Inc, H1 2017

Influenza A Virus, H3N2 Subtype Infections – Pipeline by SK Chemicals Co Ltd, H1 2017

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017

Influenza A Virus, H3N2 Subtype Infections – Pipeline by VBI Vaccines Inc, H1 2017

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Visterra Inc, H1 2017

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Zydus Cadila Healthcare Ltd, H1 2017

Influenza A Virus, H3N2 Subtype Infections – Dormant Projects, H1 2017

Influenza A Virus, H3N2 Subtype Infections – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports